Outlook Therapeutics, Inc.OTLKNASDAQ
LOADING
|||
Net Income Growth Trend
Above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
0.00%
↑ 100% above average
Average (39q)
-51.90%
Historical baseline
Range
High:205.36%
Low:-922.45%
Volatility
-2172.9%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | 56.53% |
| Q1 2025 | -366.76% |
| Q4 2024 | 205.36% |
| Q3 2024 | -87.19% |
| Q2 2024 | 138.86% |
| Q1 2024 | -922.45% |
| Q4 2023 | 13.96% |
| Q3 2023 | 37.17% |
| Q2 2023 | -210.72% |
| Q1 2023 | 64.35% |
| Q4 2022 | -30.10% |
| Q3 2022 | 18.22% |
| Q2 2022 | 10.99% |
| Q1 2022 | -36.24% |
| Q4 2021 | -7.90% |
| Q3 2021 | -9.90% |
| Q2 2021 | 6.94% |
| Q1 2021 | 9.33% |
| Q4 2020 | -45.70% |
| Q3 2020 | -229.09% |
| Q2 2020 | 47.11% |
| Q1 2020 | 65.67% |
| Q4 2019 | -64.45% |
| Q3 2019 | -127.34% |
| Q2 2019 | 56.65% |
| Q1 2019 | -5.16% |
| Q4 2018 | 20.15% |
| Q3 2018 | -44.69% |
| Q2 2018 | -11.83% |
| Q1 2018 | -292.50% |
| Q4 2017 | 69.86% |
| Q3 2017 | -19.55% |
| Q2 2017 | 33.74% |
| Q1 2017 | 57.87% |
| Q4 2016 | -80.25% |
| Q3 2016 | 52.55% |
| Q2 2016 | -530.35% |
| Q1 2016 | 79.00% |
| Q4 2015 | 1.75% |